Skip to main content

July 2025

Crack GPAT — Prepare for GPAT Online 

IIIM invites applications from Microbiology, Biotechnology candidates

M.Sc Microbiology, Fermentation Technology, Biotechnology Or B.E, B.Tech. Chemical Engineering, Biochemical Engineering, Fermentation Technology, Biotechnology.
Regional Cancer Centre looking for Clinical Trial Co-ordinator - Life Sciences Apply
Help to recruit participants required for the project and explain the procedure to the participants and family members
Walk in Drive for M.Pharm, B.Pharm, MSc in QA, Production at Biological E
Biological E. Limited (BE) invites both experienced professionals and fresh diploma holders, as well as graduates and self-driven individuals
Walk in Drive for M.Pharm, B.Pharm, MSc in Production, QA, QC, Packing at Hetero
Hetero is one of worlds leading producers of key Active Pharmaceutical Ingredients (APIs) and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector.
Walk-In Drive for D.Pharm, B.Pharm, M.Pharm in Production and Packing at Alembic Pharma
Handle manufacturing skids, Fedegari autoclaves isolator, lyophilizers, vial washing and tunnel, vial/ ophthalmic/ PFS filling and aseptic filtration
Torrent Pharma looking for Biopharmaceutics Executive - M.Pharm Apply
Preparation/review of medical and scientific write up. Coordination for serious adverse event reporting and safety update to Regulatory agency
Walk in Drive for D.Pharm, B.Pharm, M.Pharm, MSc in Production, Microbiology, QA and QC at Indoco Remedies
Knowledge of handling HPLC, UV, Karl Fischer, Autotitrator, GC and dissolution in sterile and non-sterile.
Walk in Drive for M.Pharm, B.Pharm, MSc in QC, Packing, Microbiology at Intas Pharma
Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world.
NATCO Pharma’s Mekaguda API unit receives EIR from U.S. FDA following June inspection
NATCO Pharmas Active Pharmaceutical Ingredient (API) facility located in Mekaguda, near Hyderabad, has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration
Zydus receives tentative USFDA approval for Ibrutinib tablets in multiple strengths
Zydus Lifesciences Limited has received tentative approval from the U.S. Food and Drug Administration (USFDA) to market Ibrutinib tablets in three strengths — 140 mg, 280 mg, and 420 mg. The approved products are generic versions of Imbruvica®, a widely used cancer medication in the United States.